 SAN DIEGO, CA ACCESSWIRE November 11, 2021 Dermata Therapeutics, Inc. Dermata, or the Company NASDAQ:DRMA, a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will host a virtual investor event to present the DMT410 Phase 1b results in multiple aesthetic skin conditions on Friday, November 19, 2021 at 4:30 pm ET. The virtual investor event will feature a presentation by Dermatas Senior Vice President of Development, Dr. Christopher Nardo and Chairman, President, and Chief Executive Officer, Gerry Proehl. 